Letizia Pontolillo
Overview
Explore the profile of Letizia Pontolillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicolo E, Serafini M, Munoz-Arcos L, Pontolillo L, Molteni E, Bayou N, et al.
J Liq Biopsy
. 2025 Mar;
2:100117.
PMID: 40028485
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and...
2.
Pontolillo L, Gouda M, Venetis K, Nicolo E, Reduzzi C
J Liq Biopsy
. 2025 Mar;
7:100286.
PMID: 40027228
No abstract available.
3.
Taralli S, Orlandi A, Pafundi P, Tempesta V, Di Leone A, Pontolillo L, et al.
Radiol Med
. 2025 Feb;
130(3):422-437.
PMID: 39937369
Purpose: To investigate metabolic parameters from baseline F-FDG PET/CT as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and disease recurrence in locally advanced breast cancer (LABC) patients....
4.
Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):11.
PMID: 39910103
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR)...
5.
Belluomini L, Avancini A, Sposito M, Pontolillo L, Tregnago D, Trestini I, et al.
Crit Rev Oncol Hematol
. 2024 Jul;
201:104444.
PMID: 39002789
Over the years, advancements in antiemetic drugs have improved chemotherapy-induced nausea and vomiting (CINV) control. However, despite the antiemetics therapies, in a relevant number of adult patients (∼30 %), CINV...
6.
Nicolo E, Gianni C, Pontolillo L, Serafini M, Munoz-Arcos L, Andreopoulou E, et al.
Transl Breast Cancer Res
. 2024 May;
5:10.
PMID: 38751670
Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering a minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of the...
7.
Miglietta F, Pontolillo L, De Angelis C, Caputo R, Marino M, Bria E, et al.
Breast
. 2024 Mar;
75():103713.
PMID: 38493590
Background: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in...
8.
Sposito M, Belluomini L, Pontolillo L, Tregnago D, Trestini I, Insolda J, et al.
J Pers Med
. 2023 Oct;
13(10).
PMID: 37888038
Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT in resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung cancer (NSCLC), and breast cancer...
9.
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231173180.
PMID: 37284523
Background: In early breast cancer (BC) the impact of denosumab on survival outcomes is still unclear. We undertook a systematic review and meta-analysis to assess efficacy and safety of adjuvant...
10.
Pasqualoni M, Orlandi A, Palazzo A, Garufi G, Cannizzaro M, Pontolillo L, et al.
Front Oncol
. 2023 Mar;
13:1067264.
PMID: 36969030
Cancer treatment-related adverse events (AEs) are sometimes associated with outcomes for cancer patients, especially with the newest therapies such as target therapy and immunotherapy. A few years ago, the first-line...